Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 13/20 | 0.69 |
| ▸ | CTSK | P43235 | 8/20 | 0.69 |
| ▸ | CTSL | P07711 | 6/20 | 0.68 |
| ▸ | CTSB | P07858 | 5/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | KLK7 | P49862 | 2/20 | 0.61 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30902907 | 0.91 | MAPT (0.65) | CTSSCTSKMAPTKLK7KLK5 | |
| SCHEMBL17133648 | 0.90 | MAPT (0.64) | CTSSCTSKMAPTKLK7KLK5 | |
| SCHEMBL15083460 | 0.89 | KLK7 (0.61) | CTSSCTSKCTSLCTSBMAPT | |
| SCHEMBL16288881 | 0.89 | KLK7 (0.61) | CTSSCTSKCTSLCTSBMAPT | |
| SCHEMBL23420126 | 0.89 | MAPT (0.63) | CTSSCTSKCTSLMAPTKLK7 | |
| SCHEMBL12085048 | 0.89 | MAPT (0.63) | CTSSCTSKCTSLMAPTKLK7 | |
| SCHEMBL30902797 | 0.89 | MAPT (0.62) | CTSSCTSLMAPTKLK7KLK5 | |
| SCHEMBL12148814 | 0.89 | MAPT (0.62) | MAPTKLK7KLK5 | |
| SCHEMBL9504309 | 0.89 | MAPT (0.65) | MAPTKLK7KLK5 | |
| SCHEMBL20542810 | 0.88 | SIRT2 (0.65) | MAPTKLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015755-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| EP-1452522-A2 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040147745-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | US | disclosed |
| EP-1178958-B1 | N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS | AXYS PHARM INC (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030096796-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-05-22 | — | — | US | disclosed |
| US-6455502-B1 | Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-09-24 | — | — | US | disclosed |
| EP-1178958-A2 | N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000055125-A2 | N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096796-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | CTSS 10/4885CTSK 32/4885CTSL 14/4885 |
| US-20040147745-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | CTSS 10/4885CTSK 32/4885CTSL 14/4885 |
| US-20070015755-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | CTRL, SERPINB1, CPN1 | CTSS 10/4885CTSK 32/4885CTSL 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.